COST-EFFECTIVENSS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS VS. ANGIOTENSIN II RECEPTOR BLOCKERS AS FIRST-LINE TREATMENT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

被引：0
|
作者：
Clark, L. A. [1 ]
Whitmire, S. M. [1 ]
Patton, S. [1 ]
Clark, C. A. [1 ]
Blanchette, C. M. [2 ]
机构：
[1] Univ North Carolina Charlotte, Charlotte, NC USA
[2] Univ N Carolina, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK14
引用
收藏
页码：A308 / A308
页数：1
相关论文
共 50 条
  • [21] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Sepetavc, Filip
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    CALCIFIED TISSUE INTERNATIONAL, 2022, 111 (04) : 396 - 408
  • [22] Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on peritoneal transport
    Coronel, Francisco
    KIDNEY INTERNATIONAL, 2011, 79 (01) : 136 - 137
  • [23] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Kara L. Holloway-Kew
    Amelia G. Betson
    Kara B. Anderson
    Filip Sepetavc
    James Gaston
    Mark A. Kotowicz
    Wan-Hui Liao
    Maciej Henneberg
    Julie A. Pasco
    Calcified Tissue International, 2022, 111 : 396 - 408
  • [24] Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence
    Tsouli, SG
    Liberopoulos, EN
    Kiortsis, DN
    Mikhailidis, DP
    Elisaf, MS
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (01) : 1 - 15
  • [25] Treatment for diabetic nephropathy: Angiotensin receptor blockers preferred to angiotensin-converting enzyme inhibitors
    Harman-Boehm, I
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (05): : 296 - 298
  • [26] Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 201p
    Sanchis-Gomar, Fabian
    Lavie, Carl J.
    Perez-Quilis, Carme
    Henry, Brandon M.
    Lippi, Giuseppe
    MAYO CLINIC PROCEEDINGS, 2020, 95 (06) : 1222 - 1230
  • [27] POLYCYSTIC KIDNEY-DISEASE AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS
    BURSZTYN, M
    ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) : 90 - 90
  • [28] Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney
    Thurman, JM
    Schrier, RW
    AMERICAN JOURNAL OF MEDICINE, 2003, 114 (07): : 588 - 598
  • [29] Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease
    Ripley, Elizabeth
    AMERICAN HEART JOURNAL, 2009, 157 (06) : S7 - S16
  • [30] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease
    Berger, Alan K.
    Duval, Sue
    Manske, Connie
    Vazquez, Gabriela
    Barber, Cheryl
    Miller, Leslie
    Luepker, Russell V.
    AMERICAN HEART JOURNAL, 2007, 153 (06) : 1064 - 1073
12345